That paper also mentions high levels of protein binding causing delays in pharmacokinetics. The fact that mescaline’s potency correlates in vivo and in vitro argue against its main effects being caused by some cryptic metabolite.Mescaline metabolites & ALDH inhibition
Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions - PMC
Mescaline (3,4,5-trimethoxyphenethylamine), mainly found in the Peyote cactus (Lophophora williamsii), is one of the oldest known hallucinogenic agents that influence human and animal behavior, but its psychoactive mechanisms remain poorly ...pmc.ncbi.nlm.nih.gov
I always feel that a single paper with good primary data is worth a million reviews.
This paper feels even more loose. I really don’t know what to say, but it feels like they are coming up with novel metabolic routes that can’t be detected due to forming protein adducts (which totally can be screened for by mass spec). Idk it kind of feels like they are trying to reinvent the wheel with a square wheel. They say that both 2C-X compounds and mescaline both form quinones through demethylation and oxidation, which cause their effects catalytically, but don’t explain the vast differences of pharmacokinetics.Another interesting study on mescaline activity & drugs in general
Novel, unifying mechanism for mescaline in the central nervous system: Electrochemistry, catechol redox metabolite, receptor, cell signaling and structure activity relationships - PMC
A unifying mechanism for abused drugs has been proposed previously from the standpoint of electron transfer. Mescaline can be accommodated within the theoretical framework based on redox cycling by the catechol metabolite with its quinone ...pmc.ncbi.nlm.nih.gov
Weird and far out theories can be fun, but the problem with them is that they require quite a bit of data to compete with mainstream approaches (especially when they contradict them).
